Verapamil ER

DRUG2 trials

Sponsors

Boehringer Ingelheim, Johns Hopkins University

Conditions

HealthyReversible Cerebral Vasoconstriction Syndrome

Phase 1

Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

CompletedNCT02171533

Boehringer IngelheimHealthy

Start: 2008-06-30Updated: 2014-06-24

Phase 4

RCVS: The Rational Approach to Diagnosis and Treatment

WithdrawnNCT03150524

Johns Hopkins UniversityReversible Cerebral Vasoconstriction Syndrome

Start: 2017-07-01End: 2019-05-31Updated: 2019-09-18